Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib in advanced RCC after checkpoint inhibitors
NCT03200717Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2017
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, open-label trial of pazopanib in renal cell carcinoma (RCC) (2 arms), sponsored by Novartis. Primary endpoint: Progression Free Survival up to 38 months. Started Nov 2017; status: completed.
02
Drugs
pazopanib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03200717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03200717.